[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"restless-leg-syndrome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:restless-leg-syndrome":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643070","effects-of-static-stretching-and-strength-training-on-antenatal-restless-leg-syndrome-100643070",false,"NCT07642089","Effects of Static Stretching and Strength Training on Antenatal Restless Leg Syndrome","Effects of Statics Stretching With and Without Strength Training on Symptom Severity, Fatigue and Sleep Quality in Antenatal Restless Leg Syndrome","Inclusion Criteria:\n\n* Pregnant women aged 18-35 years.\n* Gestational age between 24 and 32 weeks.\n* Diagnosed with RLS based on the International Restless Legs Syndrome Study Group (IRLSSG) criteria.\n* Experiencing sleep disturbances and fatigue related to RLS.\n\nExclusion Criteria:\n\n* High-risk pregnancies or obstetric complications.\n* Pre-existing neurological or musculoskeletal disorders.\n* Engagement in regular exercise routines prior to the study.\n* Contraindications to exercise as determined by a healthcare provider.",true,"FEMALE","18 Years","35 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","Restless Legs Syndrome (RLS) is a prevalent sensorimotor disorder affecting pregnant women, particularly in the third trimester, and is associated with sleep disturbances, fatigue and reduced quality of life. Non-pharmacological strategies such as stretching and strength training offer promising alternatives during pregnancy. This randomized controlled trial aims to compare the effects of static stretching alone and static stretching combined with strength training on sleep quality, symptom severity and fatigue in antenatal women with RLS.\n\nThirty pregnant women meeting the diagnostic criteria for RLS will be recruited from National Hospital and medical center and randomly assigned into two groups. Group A will receive static stretching exercises, while Group B will receive static stretching and lower limb strength training exercises for 6 weeks, three sessions per week. Data will be analyzed using SPSS, with a p-value \\\u003C 0.05 considered statistically significant.",[28],"Restless Leg Syndrome",[30,31,32],"Resistance training","Sleep quality","Muscle Stretching Exercise","RECRUITING","2026-06-08",{"date":36,"type":37},"2026-06-11","ACTUAL",{"date":39,"type":37},"2025-04-02",{"date":41,"type":22},"2026-08-15",{"name":43,"class":44},"Riphah International University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":53,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100601474","the-suggested-immobilization-test-with-exploratory-heart-rate-variability-analysis-for-diagnosis-of-restless-legs-syndrome-100601474","NCT07110961","The Suggested Immobilization Test With Exploratory Heart Rate Variability Analysis for Diagnosis of Restless Legs Syndrome","Diagnostic Accuracy of the Suggested Immobilization Test With Exploratory Heart Rate Variability Analysis for Restless Legs Syndrome in a Thai Population","Inclusion Criteria:\n\n* Patients who were appointed for an in-lab polysomnographic study and fit the clinical diagnosis criteria for restless leg syndrome based on International Restless Legs Syndrome Study Group (IRLSSG)\n\nExclusion Criteria:\n\n* Patient with physical limitations including stroke, dementia or hearing impairment\n* Pregnant women","ALL","70 Years",{"count":56,"type":22},52,[25],"Restless leg syndrome (RLS) is not uncommon and can also affect people's health and quality of life. Mainly, RLS is diagnosed based on clinical criteria subjectively. Sometimes it is difficult to differentiate between RLS and mimickers, especially in patients with comorbidities such as diabetes or parkinson's disease. We believe that using objective tests would facilitate accuracy in RLS diagnosis, which leads to proper management of patients.",[28],[61,62,63],"restless leg syndrome","sleep","suggested immobilization test","2026-02-10",{"date":66,"type":37},"2026-02-13",{"date":68,"type":37},"2025-10-01",{"date":70,"type":22},"2026-12-31",{"name":72,"class":44},"Siriraj Hospital",{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":53,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100610234","phase-2-tolerability-and-efficacy-of-cbd-extract-for-rls-treatment-100610234","NCT07224932","Tolerability and Efficacy of CBD Extract for RLS Treatment","A Randomized, Double-blind, Placebo-controlled Parallel Study of the Tolerability and Efficacy of High Cannabidiol (CBD) Cannabis Extract for the Treatment of Patients With Idiopathic Restless Legs Syndrome (RLS)","Inclusion Criteria:\n\n1. Male or female subjects between 18 and 79 years of age, inclusive.\n2. Willing and able to give informed consent.\n3. Idiopathic RLS, meeting all 4 International RLS Study Group diagnostic criteria.\n4. Moderate or severe symptoms, defined as an IRLS score ≥ 15 at screening visit.\n5. RLS medications unchanged for 4 weeks prior to baseline.\n6. Must have a driver or available transportation (including provided Uber vouchers) to drive them to and from study visits and for other transportation needs during the treatment period.\n7. Has a significant other, caregiver, or close acquaintance who knows the subject well and agrees to participate in the subject's neuropsychiatric assessment.\n8. Agrees to not take more than 1 gram per day of acetaminophen.\n9. Whereas applicable, agrees to utilize an effective method of contraception from screening through at least 4 weeks after the completion of study treatment.\n\nExclusion Criteria:\n\n1. Secondary RLS, such as Parkinson's disease or end-stage renal disease.\n2. Present or past history of another severe sleep disorder.\n3. Currently on night shift work schedule.\n4. History or diagnosis of schizophrenia, bipolar or a psychotic disorder, severe depression, or any mental health illness that would compromise the safety of the participant.\n5. Current suicidal ideation.\n6. Severe cognitive impairment (e.g., Alzheimer's Disease, traumatic brain injury).\n7. Uncontrolled hypertension.\n8. Known or suspected allergy or hypersensitivity to cannabinoids or excipients used in the study drug formulation.\n9. Pending legal action or workers compensation.\n10. Cannabis use (THC) detectable at the screening\u002Fbaseline visits.\n11. History of drug or alcohol dependence.\n12. Use of dopamine blockers, cocaine, or MAO-A inhibitors within 90 days of baseline.\n13. Use of any drugs with known interactions with cannabinoids (e.g., tolcapone, clopidogrel, felbamate, warfarin, barbiturates, benzodiazepines, niacin, nicotinamide, isoniazid, ketoconazole, clobazam, valproate, mTOR inhibitors) within 90 days of baseline.\n14. Unstable medical condition.\n15. Clinically significant laboratory abnormalities.\n16. Moderate or severe hepatic impairment.\n17. Is pregnant, lactating, or has a positive pregnancy test result pre-dose.\n18. Planned elective surgery during study participation.","79 Years",{"count":82,"type":22},60,[84],"PHASE2","This study plans to learn more about the safety and tolerability of high Cannabidiol (CBD) cannabis extract (BRC-002) for use in Idiopathic Restless Legs Syndrome. Symptoms and side effects experienced while taking the study drug will be tracked to determine if this medication is safe to use.",[28],[28,88,89],"cannabis","BRC-002","NOT_YET_RECRUITING","2025-11-11",{"date":93,"type":37},"2025-11-13",{"date":95,"type":22},"2025-12-19",{"date":97,"type":22},"2026-02-25",{"name":99,"class":44},"University of Colorado, Denver"]